What is glycopyrrolate used for?

Indications and Usage, quoted from the label by Sandoz Inc (ANDA211334). Cross-references to other label sections are left out.

Preanesthetic

Glycopyrrolate injection is indicated in adults and pediatric patients for reduction of salivary, tracheobronchial, and pharyngeal secretions, reduction of volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation.

Intraoperative

Glycopyrrolate injection is indicated in adults and pediatric patients to counteract surgically or drug-induced or vagal reflex-associated arrhythmias.

Reversal of Neuromuscular Blockade

Glycopyrrolate injection is indicated in adults and pediatric patients for protection against peripheral muscarinic effects of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing agents.

Peptic Ulcer

Glycopyrrolate injection is indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.

• Limitations of Use

Glycopyrrolate injection is not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.

Source: DailyMed label, set id cb1ae370-ec4f-4114-9860-8f736f72b545, version 11, effective April 1, 2026. NDC 0781-3825, one of 85 listings for this product.

Indications and Usage, quoted from the label by Aurolife Pharma LLC (ANDA202675). Cross-references to other label sections are left out.

Glycopyrrolate tablets are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.

Limitations of Use Glycopyrrolate tablets are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.

Source: DailyMed label, set id 677f8495-a870-45b6-bb65-75b449f040ce, version 9, effective December 11, 2025. NDC 13107-014, one of 45 listings for this product.

Indications and Usage, quoted from the label by Fresenius Kabi USA, LLC (ANDA209328). Cross-references to other label sections are left out.

Anesthesia

Glycopyrrolate Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection may be used intraoperatively to counteract surgically or drug induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants.

Peptic Ulcer

For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.

Source: DailyMed label, set id ccafb5c2-86dd-4bb2-883a-c13e3171227c, version 3, effective October 14, 2024. NDC 63323-578, one of 32 listings for this product.